Whitney & Co’s Cytokinetics CYTK Stock Holding History

Whitney & Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Buy	3,253 +13	+0.4%	+$933	0.02%	153
2026 Q1	$214K	Buy	+3,240	New	+$206K	0.02%	164

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Whitney & Co's CYTK Position: Q2 2026 in Review

Whitney & Co increased its Cytokinetics (CYTK) stake by 0.4% in Q2 2026, buying an estimated $933 and bringing the position to 3,253 shares worth $277K. The position accounts for 0.02% of the portfolio, ranked #153.

Whitney & Co first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Whitney & Co held 3,253 shares of Cytokinetics worth $277K as of Q2 2026.
Whitney & Co bought 13 Cytokinetics shares in Q2 2026, an estimated $933.
Cytokinetics made up 0.02% of Whitney & Co's portfolio in Q2 2026, its #153 holding.
Whitney & Co first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Whitney & Co's 13F filing for Q2 2026, filed 28 Jul 2026.